- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07948408
A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)
An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.
This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Wei Zhong, PhD
- Número de teléfono: 1-951-547-4692
- Correo electrónico: wei.zhong@wayshinebiopharm.com
Copia de seguridad de contactos de estudio
- Nombre: Lily Liu, MD
- Número de teléfono: +8613818880308
- Correo electrónico: lily.liu@wayshinebiopharm.com
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200123
- Shanghai East Hospital
-
Contacto:
- Fei Zhou, MD
- Número de teléfono: +86 21-38804518
- Correo electrónico: fei.zhou@tongji.edu.cn
-
Investigador principal:
- Caicun Zhou, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC
- Eligible for platinum-based doublet chemotherapy
- Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
- Tissue sample confirmed C797S positive by central lab using NGS
- At least one measurable target lesion per RECIST v1.1 criteria
- ECOG 0-1
- Adequate organ function and bone marrow function
- Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
- Male participants should agree to the use of contraceptive measures
Exclusion Criteria:
- Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
- Histological or phenotypic transformation
- Any severe or uncontrolled systemic disease
- ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
- Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
- A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
- Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
- Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
- Poorly controlled diabetes mellitus or hypertension
- History of other primary malignancies within two years
- Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
- Active infectious diseases (e.g., active HIV, HBV and HCV)
- Known alcohol or drug dependence
- Mental disorders or poor compliance
- The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: WSD0922-FU Tablet
|
Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Otros nombres:
|
|
Comparador activo: Platinum-Based Doublet Chemotherapy
|
Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression Free Survival (PFS)
Periodo de tiempo: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1 |
From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
OS |
From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PFS as assessed by investigator per RECIST 1.1
Periodo de tiempo: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
|
Objective Response Rate (ORR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
ORR as assessed by investigator and BICR per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Duration of Response (DOR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DoR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Disease Control Rate (DCR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DCR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Disease Progression (TTP)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTP by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Response (TTR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial ORR (icORR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icORR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial PFS (icPFS)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icPFS by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DOR (icDOR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDOR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DCR (icDCR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDCR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTP (icTTP)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTP by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTR (icTTR)
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
AE and SAE
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
AE and SAE per CTCAE 6.0 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Periodo de tiempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Caicun Zhou, MD, Shanghai East Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Neoplasias del Sistema Nervioso
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias del Sistema Nervioso Central
- Carcinoma de pulmón de células no pequeñas
- Neoplasias Cerebrales
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Compuestos de platino
- Pemetrexed
- Carboplatino
- Cisplatino
Otros números de identificación del estudio
- WSD0922-301
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .